Home CONTACT Neoplasma 2007 Neoplasma Vol.54, p.123-126, 2007

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.54, p.123-126, 2007

Title: DAPK1 promoter hypermethylaiton in brain metastases and peripheral blood
Author: V. MARTINEZ-GLEZ, C. FRANCO-HERNANDEZ, P. GONZALEZ-GOMEZ, A. ISLA, J. M. DE CAMPOS, J. VAQUERO, M. GUTIERREZ, C. CASARTELLI, J. A. REY

Abstract: The DAPK1 gene works as a regulator of apoptosis and is frequently inactivated in cancer by aberrant promoter hypermethylation. Loss of DAPK1 expression is associated with a selective advantage for tumor cells to resist apoptotic stimuli, allowing them to separate from the original tumor; from this point of view, DAPK1 could be considered a tumor metastases inhibitor gene. To verify the participation of DAPK1 silencing in cerebral invasion, we analyzed its promoter methylation status in a series of 28 samples from cerebral metastases using MSP and sequencing of the MSP-product. We have found hypermethylation in 53.6% (15/28) metastatic tumor samples as well as in 27.8% (5/18) of its peripheral blood samples. Our data suggest an important role of DAPK1 for silencing through promoter CpG island hypermethylation in the development of brain metastases from solid tumors. The detection of aberrant hypermethylation on DAPK1 promoter from peripheral blood samples has potential clinical implications as a tumor prognosis marker.

Keywords: DAPK1, Brain Metastases, Promoter Hypermethylation
Year: 2007, Volume: 54, Issue: Page From: 123, Page To: 126

Price: 9.60 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.